Roche sees positive data in lung cancer immunotherapy first

Jun 25, 2018

Roche announced positive survival data in a trial that the drugmaker hopes will yield the first immunotherapy cocktail to be approved as an initial treatment for an aggressive form of lung cancer.

According to the Phase 3 trial results, Tecentriq, combined with chemotherapy, significantly boosted overall survival of patients with previously untreated extensive-stage small cell lung cancer compared with chemotherapy alone. Small cell lung cancers account for 10-15 percent of all lung cancers, according to the American Cancer Society.

“These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer, a particularly difficult-to-treat type of disease,” said Sandra Horning, Roche’s chief medical officer.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments